Last reviewed · How we verify
IND Application
What an IND contains
An IND has three core sections: (1) Animal pharmacology + toxicology — including GLP-quality safety studies in rodents + non-rodents; (2) Manufacturing CMC (Chemistry, Manufacturing, Controls) — describes how the drug is made + quality-controlled; (3) Clinical protocols + investigator information — the proposed Phase 1 trial design, investigator brochure, and prior human experience if any. The package typically runs 5,000-50,000 pages.
The 30-day clock
After filing, the FDA has 30 days to object. If silent, the IND becomes effective and Phase 1 can start. The FDA can place a "Clinical Hold" before activation if there are safety, manufacturing, or design concerns. ~30% of INDs receive at least one Clinical Hold during their lifetime. Holds are usually resolved by amendment within months.
IND types
(1) Commercial IND — sponsored by a company pursuing eventual marketing approval (most common); (2) Investigator IND — sponsored by a physician/researcher for specific patient(s); (3) Expanded Access IND — for patients with serious diseases who can't join a clinical trial (compassionate use). Different requirements for each.
Pre-IND meeting
Sponsors typically request a pre-IND meeting with the FDA before filing. This is a 1-2 hour discussion of preclinical data, proposed Phase 1 design, and any specific FDA concerns. Sponsors who don't request pre-IND meetings have higher Clinical Hold rates.
FAQ
How much does an IND cost?
Preparation of the IND package itself runs $1-5M including regulatory consulting + preclinical studies. The FDA does NOT charge a user fee for IND filing (user fees apply only at the NDA/BLA filing stage).
Can a Phase 1 trial start before the IND is effective?
No — Phase 1 must wait for IND effectiveness (30 days post-filing, or sooner if FDA explicitly clears the hold).
What's the difference between an IND + NDA?
IND is to BEGIN trials; NDA is to register the drug for marketing AFTER trials are complete. IND happens early (pre-Phase 1); NDA happens late (post-Phase 3). Same FDA division but different statutory mechanisms.